Roche discontinued two Huntington’s disease antisense programs with Ionis—halting the Phase 2 GENERATION HD2 study of tominersen after it failed a key efficacy objective and stopping a separate trial of RG6496 after new data from a parallel animal study. Roche cited the “totality of data,” with a company spokesperson describing the outcome as “deeply disappointing.” The decision follows earlier trouble for tominersen: Roche previously suspended an early-stage study after catheter-related infections and ended the Phase 3 GENERATION HD1 trial after a pre-planned benefit/risk review. Roche and Ionis said they will continue working on other programs. Separately, the FDA rejected the Hengrui-Elevar liver cancer drug combination for the third time in about two years, citing manufacturing deficiencies. The repeat refusal underscores how supply-chain and process issues can become decisive even when clinical rationale is established.